Vaishali Pharma Ltd (VAISHALI) — shareholding pattern, promoter holding, financials and share price
About Vaishali Pharma Ltd (VAISHALI)
Vaishali Pharma Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as VAISHALI and on the BSE under scrip code 535000. Its ISIN is INE972X01022.
Incorporated in 1989, Vaishali Pharma Ltd does marketing of pharmaceutical products including active pharmaceutical ingredients [1]
Vaishali Pharma Limited is a pharmaceutical company that deals in formulations, APIs, surgical products, veterinary supplements, and nutraceutical products. The company operates in both domestic and international markets, focusing on API trading locally and marketing a broader range of products abroad.
The company has established a strong international presence with over 250 formulation brands across various countries, showcasing a diversified product pipeline and strategic manufacturing collaborations.
Listed peers in Pharmaceuticals: Sotac Pharmaceuticals Ltd, Par Drugs & Chemicals Ltd, Denis Chem Lab Ltd, Mercury Laboratories Ltd, Concord Drugs Ltd, Makers Laboratories Ltd.
Valuation & Returns
10 Jul 2026At ₹7.56 a share on 10 Jul 2026, Vaishali Pharma Ltd (VAISHALI) was valued at a price-to-earnings ratio of 27.56x and a price-to-book of 1.71x on a book value of ₹4.42 per share as of Mar 2025. Solomo computes return on equity of 6.21% and return on capital employed of 9.53% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 27.56x
- P/B
- 1.71x
- EPS (TTM)
- ₹0.27
- Book value / share
- ₹4.42
- ROE
- 6.21%
- ROCE
- 9.53%
- ROA
- 3.67%
- Debt / equity
- 0.19x
- Dividend yield
- 0.2%
- EBITDA margin
- 18.78%
- 52-week range
- ₹100 – ₹139.65
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Vaishali Pharma Ltd (VAISHALI) reported revenue of ₹109 crore, net profit of ₹4 crore and earnings per share of ₹0.32. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹26.93 crore and net profit ₹0.41 crore (consolidated).
| Metric | Mar 2026 |
|---|---|
| Revenue (₹ cr) | 109 |
| Net profit (₹ cr) | 4 |
| EPS (₹) | 0.32 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 10.51% | 9.31% | 14.78% |
| Profit growth | 90.26% | -41.21% | 13.89% |
| Stock price CAGR | 13% | -14% | -39% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 31.61% of Vaishali Pharma Ltd (VAISHALI) (unchanged from the previous quarter). Market capitalisation was ₹111 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2017.
Largest disclosed public shareholders in Jun 2026: SAPAN ANIL SHAH 6.16%, NUPUR ANIL SHAH 3.27%, RENU PITTIE 1.74%, SONAL SANJAY MIRANI 1.57%, SANJAY GIRDHARILAL MIRANI 1.53%, KIRIT CHIMANLAL TOLIA 1.3%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 31.61% | - | - | - | - |
| Mar 2026 | 31.61% | - | - | - | - |
| Dec 2025 | 31.61% | - | - | - | - |
| Sep 2025 | 26.32% | - | - | - | - |
| Jun 2025 | 26.32% | - | - | - | - |
| Mar 2025 | 26.32% | - | - | - | - |
| Dec 2024 | 26.32% | - | - | - | - |
| Sep 2024 | 26.32% | - | - | - | - |